Genetic variants in C-type lectin genes are associated with colorectal cancer susceptibility and clinical outcome

International Journal of Cancer

Volumn 133, Issue 10, 2013, Pages 2325-2333

  Lu, Shun ^a   Bevier, Melanie ^a   Huhn, Stefanie ^a   Sainz, Juan ^a   Lascorz, Jesus ^a   Pardini, Barbara ^b,c   Naccarati, Alessio ^b,c   Vodickova, Ludmila ^b,d   Novotny, Jan ^e   Hemminki, Kari ^a,f   Vodicka, Pavel ^b,d   Försti, Asta ^a,f  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Czech Republic)

^c Human Genetics Foundation   (Italy)

^d CHARLES UNIVERSITY   (Czech Republic)

^e CHARLES UNIVERSITY   (Czech Republic)

^f LUND UNIVERSITY   (Sweden)

Author keywords

CD209; colorectal cancer; MBL; polymorphism; REG4

Indexed keywords

CD209 ANTIGEN; LECTIN; MANNOSE BINDING LECTIN 2;

3' UNTRANSLATED REGION; ADULT; AGE; AGED; ALLELE; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CD209 GENE; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; CZECH REPUBLIC; DISTANT METASTASIS; EVENT FREE SURVIVAL; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MBL2 GENE; ONCOGENE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; REGENERATING GENE 4; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

CD209; COLORECTAL CANCER; MBL; POLYMORPHISM; REG4;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LECTINS, C-TYPE; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK;

EID: 84883769767     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28251     Document Type: Article

References (42)

1. Ferlay J, Parkin DM, Steliarova-Foucher E,. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765-81.
2. Vannucci L,. Cancer immunology and colorectal cancer recurrence. Front Biosci (Schol Ed) 2011; 3: 1421-31.
3. Cambi A, Figdor C,. Necrosis: C-type lectins sense cell death. Curr Biol 2009; 19: R375-8.
4. Drickamer K,. C-type lectin-like domains. Curr Opin Struct Biol 1999; 9: 585-90.
5. van Gisbergen KP, Aarnoudse CA, Meijer GA, Geijtenbeek TB, van Kooyk Y,. Dendritic cells recognize tumor-specific glycosylation of carcinoembryonic antigen on colorectal cancer cells through dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin. Cancer Res 2005; 65: 5935-44.
6. Nonaka M, Ma BY, Murai R, Nakamura N, Baba M, Kawasaki N, Hodohara K, Asano S, Kawasaki T,. Glycosylation-dependent interactions of C-type lectin DC-SIGN with colorectal tumor-associated Lewis glycans impair the function and differentiation of monocyte-derived dendritic cells. J Immunol 2008; 180: 3347-56.
7. Nonaka M, Ma BY, Imaeda H, Kawabe K, Kawasaki N, Hodohara K, Andoh A, Fujiyama Y, Kawasaki T,. Dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN) recognizes a novel ligand, Mac-2-binding protein, characteristically expressed on human colorectal carcinomas. J Biol Chem 2011; 286: 22403-13.
8. Ytting H, Jensenius JC, Christensen IJ, Thiel S, Nielsen HJ,. Increased activity of the mannan-binding lectin complement activation pathway in patients with colorectal cancer. Scand J Gastroenterol 2004; 39: 674-9.
9. Ytting H, Christensen IJ, Jensenius JC, Thiel S, Nielsen HJ,. Preoperative mannan-binding lectin pathway and prognosis in colorectal cancer. Cancer Immunol Immunother 2005; 54: 265-72.
10. Ytting H, Christensen IJ, Steffensen R, Alsner J, Thiel S, Jensenius JC, Hansen U, Nielsen HJ,. Mannan-binding lectin (MBL) and MBL-associated serine protease 2 (MASP-2) genotypes in colorectal cancer. Scand J Immunol 2011; 73: 122-7.
11. Zanetti KA, Haznadar M, Welsh JA, Robles AI, Ryan BM, McClary AC, Bowman ED, Goodman JE, Bernig T, Chanock SJ, Harris CC,. 3′-UTR and functional secretor haplotypes in mannose-binding lectin 2 are associated with increased colon cancer risk in African Americans. Cancer Res 2012; 72: 1467-77.
12. Violette S, Festor E, Pandrea-Vasile I, Mitchell V, Adida C, Dussaulx E, Lacorte JM, Chambaz J, Lacasa M, Lesuffleur T,. Reg IV, a new member of the regenerating gene family, is overexpressed in colorectal carcinomas. Int J Cancer 2003; 103: 185-93.
13. Oue N, Mitani Y, Aung PP, Sakakura C, Takeshima Y, Kaneko M, Noguchi T, Nakayama H, Yasui W,. Expression and localization of Reg IV in human neoplastic and non-neoplastic tissues: Reg IV expression is associated with intestinal and neuroendocrine differentiation in gastric adenocarcinoma. J Pathol 2005; 207: 185-98.
14. Oue N, Kuniyasu H, Noguchi T, Sentani K, Ito M, Tanaka S, Setoyama T, Sakakura C, Natsugoe S, Yasui W,. Serum concentration of Reg IV in patients with colorectal cancer: overexpression and high serum levels of Reg IV are associated with liver metastasis. Oncology 2007; 72: 371-80.
15. Rafa L, Dessein AF, Devisme L, Buob D, Truant S, Porchet N, Huet G, Buisine MP, Lesuffleur T,. REG4 acts as a mitogenic, motility and pro-invasive factor for colon cancer cells. Int J Oncol 2010; 36: 689-98.
16. Zhou T, Chen Y, Hao L, Zhang Y,. DC-SIGN and immunoregulation. Cell Mol Immunol 2006; 3: 279-83.
17. van Kooyk Y, Geijtenbeek TB,. DC-SIGN: escape mechanism for pathogens. Nat Rev Immunol 2003; 3: 697-709.
18. Jack DL, Klein NJ, Turner MW,. Mannose-binding lectin: targeting the microbial world for complement attack and opsonophagocytosis. Immunol Rev 2001; 180: 86-99.
19. Madsen HO, Garred P, Thiel S, Kurtzhals JA, Lamm LU, Ryder LP, Svejgaard A,. Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein. J Immunol 1995; 155: 3013-20.
20. Gomi K, Tokue Y, Kobayashi T, Takahashi H, Watanabe A, Fujita T, Nukiwa T,. Mannose-binding lectin gene polymorphism is a modulating factor in repeated respiratory infections. Chest 2004; 126: 95-9.
21. Baccarelli A, Hou L, Chen J, et al. Mannose-binding lectin-2 genetic variation and stomach cancer risk. Int J Cancer 2006; 119: 1970-5.
22. Frank B, Hoffmeister M, Klopp N, Illig T, Chang-Claude J, Brenner H,. Polymorphisms in inflammatory pathway genes and their association with colorectal cancer risk. Int J Cancer 2010; 127: 2822-30.
23. Mockelmann N, von Schonfels W, Buch S, et al. Investigation of innate immunity genes CARD4, CARD8 and CARD15 as germline susceptibility factors for colorectal cancer. BMC Gastroenterol 2009; 9: 79.
24. Castro FA, Forsti A, Buch S, et al. TLR-3 polymorphism is an independent prognostic marker for stage II colorectal cancer. Eur J Cancer 2011; 47: 1203-10.
25. Pechlivanis S, Bermejo JL, Pardini B, Naccarati A, Vodickova L, Novotny J, Hemminki K, Vodicka P, Forsti A,. Genetic variation in adipokine genes and risk of colorectal cancer. Eur J Endocrinol 2009; 160: 933-40.
26. Vasen HF, Watson P, Mecklin JP, Lynch HT,. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology 1999; 116: 1453-6.
27. Pardini B, Kumar R, Naccarati A, Prasad RB, Forsti A, Polakova V, Vodickova L, Novotny J, Hemminki K, Vodicka P,. MTHFR and MTRR genotype and haplotype analysis and colorectal cancer susceptibility in a case-control study from the Czech Republic. Mutat Res 2011; 721: 74-80.
28. Nelis M, Esko T, Magi R, et al. Genetic structure of Europeans: a view from the North-East. PLoS One 2009; 4: e5472.
29. Wong KK, Tsang YT, Shen J, Cheng RS, Chang YM, Man TK, Lau CC,. Allelic imbalance analysis by high-density single-nucleotide polymorphic allele (SNP) array with whole genome amplified DNA. Nucleic Acids Res 2004; 32: e69.
30. Paez JG, Lin M, Beroukhim R, et al. Genome coverage and sequence fidelity of phi29 polymerase-based multiple strand displacement whole genome amplification. Nucleic Acids Res 2004; 32: e71.
31. Nyholt DR,. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet 2004; 74: 765-9.
32. Li J, Ji L,. Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity (Edinb) 2005; 95: 221-7.
33. Nunez C, Rueda B, Martinez A, Maluenda C, Polanco I, Lopez-Nevot MA, Ortega E, Sierra E, Gomez de la Concha E, Urcelay E, Martin J,. A functional variant in the CD209 promoter is associated with DQ2-negative celiac disease in the Spanish population. World J Gastroenterol 2006; 12: 4397-400.
34. Kobayashi K, Yuliwulandari R, Yanai H, Lien LT, Hang NT, Hijikata M, Keicho N, Tokunaga K,. Association of CD209 polymorphisms with tuberculosis in an Indonesian population. Hum Immunol 2011; 72: 741-5.
35. Wang L, Chen RF, Liu JW, Lee IK, Lee CP, Kuo HC, Huang SK, Yang KD,. DC-SIGN (CD209) Promoter-336 A/G polymorphism is associated with dengue hemorrhagic fever and correlated to DC-SIGN expression and immune augmentation. PLoS Negl Trop Dis 2011; 5: e934.
36. Sakuntabhai A, Turbpaiboon C, Casademont I, et al. A variant in the CD209 promoter is associated with severity of dengue disease. Nat Genet 2005; 37: 507-13.
37. Liu H, Yu W, Liou LY, Rice AP,. Isolation and characterization of the human DC-SIGN and DC-SIGNR promoters. Gene 2003; 313: 149-59.
38. Balaguer F, Moreira L, Lozano JJ, et al. Colorectal cancers with microsatellite instability display unique miRNA profiles. Clin Cancer Res 2011; 17: 6239-49.
39. Madsen HO, Satz ML, Hogh B, Svejgaard A, Garred P,. Different molecular events result in low protein levels of mannan-binding lectin in populations from southeast Africa and South America. J Immunol 1998; 161: 3169-75.
40. Bernig T, Breunis W, Brouwer N, Hutchinson A, Welch R, Roos D, Kuijpers T, Chanock S,. An analysis of genetic variation across the MBL2 locus in Dutch Caucasians indicates that 3′ haplotypes could modify circulating levels of mannose-binding lectin. Hum Genet 2005; 118: 404-15.
41. Numata M, Oshima T, Yoshihara K, et al. Relationship between RegIV gene expression to outcomes in colorectal cancer. J Surg Oncol 2011; 104: 205-9.
42. Brenner H, Haug U, Arndt V, Stegmaier C, Altenhofen L, Hoffmeister M,. Low risk of colorectal cancer and advanced adenomas more than 10 years after negative colonoscopy. Gastroenterology 2010; 138: 870-6.